stockrowLiquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
Follow LQDA
Alert me
Liquidia Corporation (LQDA) EBITDA
Liquidia Corporation's EBITDA for fiscal 2025 was −$49.8M, compared with −$119.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was $170.3M. Over the past ten years it has ranged from −$119.1M (fiscal 2024) to −$15.2M (fiscal 2016); the current reading is higher than 36% of that period. Liquidia Corporation ranks 20th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$49.8M | — |
| FY2024 | −$119.1M | — |
| FY2023 | −$71.2M | — |
| FY2022 | −$35.1M | — |
| FY2021 | −$28.2M | — |
| FY2020 | −$56.0M | — |
| FY2019 | −$44.2M | — |
| FY2018 | −$15.8M | — |
| FY2017 | −$17.3M | — |
| FY2017 | −$27.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $85.9M | 38.57% |
| Mar 2026 | $62.0M | 208.36% |
| Dec 2025 | $20.1M | 796.43% |
| Sep 2025 | $2.2M | — |
| 32 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $664.9M |
| SUPN Indivior Pharmaceuticals Inc. compare | $571.0M |
| LNTH Lantheus Holdings, Inc. compare | $386.4M |
| PBH Prestige Consumer Healthcare Inc. compare | $330.9M |
| LQDA Liquidia Corporation | $170.3M |
| RGC Regencell Bioscience Holdings Limited compare | −$12.5M |
| HIMS Hims & Hers Health, Inc. compare | −$62.2M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$165.9M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$3.3B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on LQDA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement